AB569 & Respiratory Pseudomonas

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

Dr. Hassett

Dr. Hassett is a Professor in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati College of Medicine. As an expert in bacterial pathogenesis he has been working with the major CF pathogens including Pseudomonas aeruginosa (PA), Staphylococcus aureus and Burkholderia cepacia. He has over 130 published manuscripts.

In 2006, he discovered that anaerobic, acidified sodium nitrite (A-NO2-) killed mucoid PA in: (i) refractory communities known as biofilms, (ii) a mouse model of PA chronic infection and (iii) airway surface liquid derived from a CF lung transplant patient. The results of his studies were published in the prestigious Journal of Clinical Investigation.

Dr. Hassett, in collaboration with Arch, has developed and identified AB569 as a new drug candidate for treating respiratory PA infections in CF patients.

Arch has an exclusive option to license, from the University of Cincinnati, the patents protecting AB569 for the purpose of performing a human trial to commercialize the technology.